- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
 |
Bispecifics and Multivalent Antibodies
13 - 14 June 2012
|
Bispecifics and Multivalent Antibodies 2012: Europe's leading conference in showcasing cutting-edge multivalent platforms and providing pre-clinical and clinical data from the leading biopharmaceutical companies. Discover the latest approaches for multivalent formats and their therapeutic applications
Ensure that you do not miss Informa's first event Bispecifics and Multivalent Antibodies event
With over $6.5bn worth of deals being made on next-generation products, including multispecific antibodies, this booming market is one that all big pharma and small biotech are looking to get involved in. With the ever knowledge of just how superior bispecifc antibodies can therapeutically, this BRAND NEW event provides a platform for the leading biopharmaceutical companies in the field to showcase their latest platforms, explain how they are developed and how they have overcome difficulties in expression and production.
With over 20 industry case studies from leading companies in the field such as Micromet, Merrimack, F-Star, Abbott, Genentech, Pfizer and many more, this is THE CONFERENCE for those looking to future your antibody development, and discover how to optimise targeting and ensure efficient drug potency.
Key sessions to be discussed include antibody discovery, target selection, bispecific engineering, ehanced tumour targeting, CMC and regulatory development considerations, preclinical and clinical strategies and multivalency
Join us for the premier event that will provide you with the essential information needed improve your bispecific antibody and produce the most effective and profitable product possible
Hear the latest highlights from Informa's Inaugural Bispecifics & Multivalent Antibodies conference
DO NOT MISS our 2 interactive workshops and informative evening seminar
Pre-Conference Workshop: Tuesday 12 June 2012
Moving Bispecifics into the clinic: What are the considerations?
Led by: Dr Jijie Gu, Senior Principal Scientist, Abbott & Dr Raffi Tonikan, Scientist I, Protein Engineering, Biogen Idec
Evening Seminar, Discussion and Dinner: Wednesday 13 June 2012
Insight into the and Cons of the Latest Novel Tools for Recombinant Antibody Engineering
Led by Dr Dimiter Dimitor, NIH, Dr Serge Muyldermans, Vrije Universiteit Brussel, Dr Kevin Moulder, F-Star & Dr Arne Skeera, XL-Protein
Post-Conference Workshop: Friday 15 June 2012
Understanding and Assessing Immunogenicity of Bispecifics
Led by: Dr Laura DeForge, Principal Scientist, Research, Genentech, USA & Dr Yanmei Lu, Scientist, Genentech, USA
Please download brochure for further details
If you work at a university and wish to attend Bispecifics and Mulitvalent Antibodies
You’ll be pleased to know we are offering a special 50% discount to all academic participants*.
What’s more, if you have cutting-edge data that you would like to share with the audience, you can do so by submitting a FREE poster to be presented in the exhibition hall.
To take advantage of your 50% discount please contact Simon Lau, on +44 (0) 207 017 7165 or simon.lau@informa.com.
We look forward to seeing you there.
* 50% discount applies to top tier price only
Spotlight Session Sponsor
Media Partners at Bispecific & Multivalent Antibodies Conference
PART OF OUR EMPOWERED ANTIBODIES CONGRESS 2012
Over 20 industry case studies from Micromet, Merrimack, Genentech, Pfizer, F-Star, Merus, Trion Pharma and more
Over 20 industry case studies from Micromet, Merrimack, Genentech, Pfizer, F-Star, Merus, Trion Pharma and more
Dr Benno Rattel
VP, Nonclinical Development
Micromet
|
Dr Birgit Schoeberl
VP, Discovery
Merrimack
|
Dr Lioudmila Tchistiakova
Senior Director, Global Biotherapeutic Tech.
Pfizer
|
Dr Horst Lindhofer
CEO
Trion Pharma
|
We are extremely proud to present our BEST EVER SPEAKER LINE UP
Do not miss hearing from...........
- Dr Renno Battel, VP, Non-Clincial Development, Micromet, Germany
- Dr John de Kruif, CSO, Merus, The Netherlands
- Dr Greg Elson, Department Head, Manufacturing, NovImmune SA, Switzerland
- Dr Alexander Ibraghimov, Principal Scientist, Biologics, Abbott, USA
- Dr Susan E Lacy, Associate Director, Biologics, Global Pharmaceutical R&D, Abbott, USA
- Dr Markus Thomas, Senior Scientist, Discovery Oncology, Roche Diagnostics, Germany
and many more to come
Feeds | Like | Share    | Calendar |
With over 200 participants, join our linked in group for Empowered Antibodies and start networking before the event and pose your questions to the experts!
Poll
What disease applications are you developing multispecific antibodies for?
Please select an answer
NEW SPEAKER ANNOUNCEMENT
Informa are delighted to welcome Dr Matthias Peipp, Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Germany, presenting on the topic of
Bifunctional fusion proteins mimicking an induced self phenotype promote antitumoral natural killer cell cytotoxicity
To find out more about this presentation, click on the 'prorgramme/abstract updates' tab above